Diabetes News and Research

Latest Diabetes News and Research

Medical weight loss programs before bariatric surgery show no clinical benefit

Patients required by their health insurance providers to complete a six-month medical weight loss program before bariatric surgery do no better than patients who have no such requirement, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

25 Jun 2010

Abbott's new FreeStyle test strips receive FDA clearance

Following the recent clearance of its FreeStyle Lite® blood glucose test strips, Abbott (NYSE: ABT) today announced that it has also received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new FreeStyle blood glucose test strips.

25 Jun 2010

Study: Low BP levels are unhealthy for CKD patients

Recent guidelines by The National Kidney Foundation Disease Outcomes Quality Initiative (NKF KDOQI)1 call for lower target blood pressure levels in patients with chronic kidney disease (CKD).

25 Jun 2010

New scam targets diabetic Medicare beneficiaries across Indiana

A new scam is targeting diabetic Medicare beneficiaries across Indiana, reports the Indiana Association of Area Agencies on Aging (IAAAA).

24 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patients who were denied bariatric surgery for insurance reasons developed a slew of new obesity-related diseases and conditions within three years of follow-up, according to a new study presented here at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

24 Jun 2010

Patient health and safety initiatives to be highlighted at ADA annual conference

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, will highlight leading patient health and safety initiatives during the 70th annual American Diabetes Association Annual Conference June 26-28 in Orlando, FL.

From Roche Sequencing and Life Science 24 Jun 2010

Ways to manage hammertoe pain

The pain from hammertoe, a deformity that can cause one or more toes to assume a claw shape, can curtail an evening of dancing or make a favorite pair of shoes unwearable. But, according to the June issue of Mayo Clinic Health Letter, this condition often can be managed by proper footwear or simple toe coverings.

24 Jun 2010

Ingredients for an "anti-aging potion"

Aging without getting old? It's largely possible, according to the June issue of Mayo Clinic Health Letter.

24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Debiotech and STMicroelectronics today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida.

24 Jun 2010

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Much has been published of late, in medical journals as well as in the general media, concerning the national rise in both the Cesarean section and premature birth rates. While not directly connected, the two medical concerns have many interrelated variables. Nationally, the Cesarean section rate has risen to 32 percent of all births, while the rate of premature birth has climbed to just over 12 percent.

24 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

Medical weight loss programs before bariatric surgery show no clinical benefit

Abbott's new FreeStyle test strips receive FDA clearance

Study: Low BP levels are unhealthy for CKD patients

New scam targets diabetic Medicare beneficiaries across Indiana

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Risk, incidence of VTE differs between races

Patients denied insurance for bariatric surgery develop new obesity-related diseases, conditions

Patient health and safety initiatives to be highlighted at ADA annual conference

Ways to manage hammertoe pain

Ingredients for an "anti-aging potion"

Spherix to explore triglycerides for D-tagatose therapy

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in